Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
November 14, 2005
- AstraZeneca to Support Lung Cancer Awareness
November 14, 2005
- Takeda: Ethical Drug Sales Up 8.8% at \500,900 Mil.
November 14, 2005
- Eisai: Record Sales, Profits; Overseas Sales Break 50%
November 14, 2005
- Santen: Ethical Drugs Drive Growth in Sales, Profits
November 14, 2005
- Torii: Sales, Profits Hit by Slump in Major Products, TachoComb Transfer
November 14, 2005
- Japan Tobacco: Pharma Division Sales Down 0.8%
November 14, 2005
- President Dr Aoki Outlines JPMA's Stance on NHI Pricing
November 14, 2005
- Teijin: Sales of Medical and Pharmaceuticals Business Rise 8.8% to Top \51,600 Mil.
November 14, 2005
- Jiro Kawasaki Appointed Minister of Health, Labor and Welfare
November 14, 2005
- Wyeth's Anticancer Drug Pipeline Outlined
November 14, 2005
- Korosho Political Tribe Concerned about Intimacy between Mr Kawasaki and Mr Tanigaki
November 14, 2005
- OPINION
November 14, 2005
- Council Members Insist on Deep Cuts into Medical Fees, NHI Prices
November 14, 2005
- Japanese Physicians Should More Positively Approach New Drug Development: Lilly's CMO A. Breier
November 14, 2005
- Reformists Criticize Korosho's Healthcare Reform Proposals
November 14, 2005
- Council Calls For Early Approval of 5 Global Standard Drugs Not Approved in Japan
November 14, 2005
- Health Economics Status Survey: Pharmacies' Profits Rose 7.6%
November 14, 2005
- R&D NEWS IN BREIF
November 14, 2005
- REGULATORY NEWS IN BRIEF
November 7, 2005
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…